P

Peptron Inc
KOSDAQ:087010

Watchlist Manager
Peptron Inc
KOSDAQ:087010
Watchlist
Price: 293 000 KRW 1.03% Market Closed
Market Cap: ₩6.8T

Gross Margin

57.8%
Current
Improving
by 19.4%
vs 3-y average of 38.4%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
57.8%
=
Gross Profit
₩3.6B
/
Revenue
₩6.2B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
57.8%
=
Gross Profit
₩3.6B
/
Revenue
₩6.2B

Peer Comparison

Country Company Market Cap Gross
Margin
KR
Peptron Inc
KOSDAQ:087010
6.8T KRW
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.1T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
214.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
153.8B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
81.6T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
36.3B CHF
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
273.1B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
37.4B USD
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
34.7B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28B USD
Loading...
US
Waters Corp
NYSE:WAT
22.9B USD
Loading...

Market Distribution

Higher than 88% of companies in Korea
Percentile
88th
Based on 2 511 companies
88th percentile
57.8%
Low
-646.5% — 12.8%
Typical Range
12.8% — 32.2%
High
32.2% — 54 001.3%
Distribution Statistics
Korea
Min -646.5%
30th Percentile 12.8%
Median 19.7%
70th Percentile 32.2%
Max 54 001.3%

Peptron Inc
Glance View

Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care. At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.

Intrinsic Value
1 625.6 KRW
Overvaluation 99%
Intrinsic Value
Price
P
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
57.8%
=
Gross Profit
₩3.6B
/
Revenue
₩6.2B
What is Peptron Inc's current Gross Margin?

The current Gross Margin for Peptron Inc is 57.8%, which is above its 3-year median of 38.4%.

How has Gross Margin changed over time?

Over the last 3 years, Peptron Inc’s Gross Margin has increased from 57% to 57.8%. During this period, it reached a low of 30.2% on Sep 30, 2024 and a high of 57.8% on Oct 30, 2025.

Back to Top